CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). CASI Pharmaceuticals Inc (NASDAQ:CASI) stock performance was -4.79% in last session and finished the day at $1.85. Traded volume was 84,312.00million shares in the last session and the average volume of the stock remained 25.60K shares. The beta of the stock remained 1.31.

On June 25, 2014, David O’Toole resigned from his position as the Senior Vice President and Chief Financial Officer and principal financial and accounting officer of Codexis, Inc. (NASDAQ:CDXS). Mr. O’Toole’s resignation will be effective July 3, 2014. The Company has engaged an executive search firm to assist the Company in recruiting a new Chief Financial Officer. Codexis, Inc. (NASDAQ:CDXS) dropped -0.70 percent to $1.41 Wednesday on volume of 96,002.00million shares. The intra-day range of the stock was $1.40 to $1.51. Codexis, Inc. (NASDAQ:CDXS) has a market capitalization of $54.51million.

China Biologic Products (NASDAQ:CBPO) had its price objective raised by Aegis from $50.00 to $55.00 in a research report released on Tuesday morning. Aegis currently has a buy rating on the stock. China Biologic Products Inc (NASDAQ:CBPO)’s stock on July 09, 2014 reported a increase of 0.56% to the closing price of $49.86. Its fifty two weeks range is $21.86 -$51.55. The total market capitalization recorded $1.21billion. The overall volume in the last trading session was 167,112.00million shares. In its share capital, CBPO has 24.22million outstanding shares.

Revance Therapeutics Inc (NASDAQ:RVNC) on June 16 announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). Revance expects to grant the underwriters a 30-day option to acquire an additional 450,000 shares. All of the shares in the offering are to be sold by Revance. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. On Wednesday, shares of Revance Therapeutics Inc (NASDAQ:RVNC) advanced 1.06% to close the day at $31.34. Company return on investment (ROI) is 28.90% and its monthly performance is recorded as 9.39%. Revance Therapeutics Inc (NASDAQ:RVNC) quarterly revenue growth is 8.33%.

Oncolytics Biotech (USA) (NASDAQ:ONCY) said Tuesday that it has completed patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The trial, an open-label, multi-institution, two-arm phase II randomized study of patients with metastatic pancreatic cancer, is sponsored by the U.S. National Cancer Institute ( NCI ) through a clinical trials agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and ONCY. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock performance was 7.79% in last session and finished the day at $1.66. Traded volume was 933,319.00million shares in the last session and the average volume of the stock remained 242.07K shares. The beta of the stock remained 1.85.